| Mr Eric Jon Kozlow, MD | |
|
120 Davis St, Asheboro, NC 27203 | |
| (336) 629-5770 | |
| (336) 629-0130 |
| Full Name | Mr Eric Jon Kozlow |
|---|---|
| Gender | Male |
| Speciality | Allergy/immunology |
| Experience | 39 Years |
| Location | 120 Davis St, Asheboro, North Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1710943790 | NPI | - | NPPES |
| 2217701B | Other | NC | MEDICARE ID |
| 1235298589 | Other | NC | GROUP NPI |
| 50259 | Other | NC | BCBS |
| 8950259 | Medicaid | NC | |
| 0202020 | Other | UNITED HEALTHCARE | |
| 2217701A | Other | NC | MEDICARE ID |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 9500975 (North Carolina) | Secondary |
| 207K00000X | Allergy & Immunology | 9500975 (North Carolina) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Moses Cone Affiliated Physicians, Inc. | 3779635396 | 72 |
News Archive
A report in Cancer Research, a journal of the American Association for Cancer Research, highlights a new biomarker that may be useful in identifying patients with recurrent glioblastoma, or brain tumors, who would respond better to anti-vascular endothelial growth factor therapy, specifically cediranib.
McKesson Corporation today reaffirmed its earnings guidance for the fiscal year ending March 31, 2011 and the underlying key assumptions provided in its press release of May 3, 2010. As previously stated, McKesson expects to earn between $4.72 and $4.92 per diluted share for the fiscal year ending March 31, 2011.
Diuretics (water pills) work better than newer and more costly medicines in the treatment of high blood pressure and prevention of some forms of heart disease in people with type 2 diabetes, according to results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Two studies on shoulder instability in a military population were presented today by U.S. Army sports medicine surgeons at the American Academy of Orthopaedic Surgeons' annual meeting.
› Verified 9 days ago
| Entity Name | Moses Cone Affiliated Physicians, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346474103 PECOS PAC ID: 3779635396 Enrollment ID: O20090713000512 |
News Archive
A report in Cancer Research, a journal of the American Association for Cancer Research, highlights a new biomarker that may be useful in identifying patients with recurrent glioblastoma, or brain tumors, who would respond better to anti-vascular endothelial growth factor therapy, specifically cediranib.
McKesson Corporation today reaffirmed its earnings guidance for the fiscal year ending March 31, 2011 and the underlying key assumptions provided in its press release of May 3, 2010. As previously stated, McKesson expects to earn between $4.72 and $4.92 per diluted share for the fiscal year ending March 31, 2011.
Diuretics (water pills) work better than newer and more costly medicines in the treatment of high blood pressure and prevention of some forms of heart disease in people with type 2 diabetes, according to results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Two studies on shoulder instability in a military population were presented today by U.S. Army sports medicine surgeons at the American Academy of Orthopaedic Surgeons' annual meeting.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Eric Jon Kozlow, MD 100 Westwood Avenue, High Point, NC 27262-4320 Ph: (336) 883-1393 | Mr Eric Jon Kozlow, MD 120 Davis St, Asheboro, NC 27203 Ph: (336) 629-5770 |
News Archive
A report in Cancer Research, a journal of the American Association for Cancer Research, highlights a new biomarker that may be useful in identifying patients with recurrent glioblastoma, or brain tumors, who would respond better to anti-vascular endothelial growth factor therapy, specifically cediranib.
McKesson Corporation today reaffirmed its earnings guidance for the fiscal year ending March 31, 2011 and the underlying key assumptions provided in its press release of May 3, 2010. As previously stated, McKesson expects to earn between $4.72 and $4.92 per diluted share for the fiscal year ending March 31, 2011.
Diuretics (water pills) work better than newer and more costly medicines in the treatment of high blood pressure and prevention of some forms of heart disease in people with type 2 diabetes, according to results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Two studies on shoulder instability in a military population were presented today by U.S. Army sports medicine surgeons at the American Academy of Orthopaedic Surgeons' annual meeting.
› Verified 9 days ago